Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)

NCT01652157 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01652157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01652157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Long-Term Prospective Observational Safety Study of the Incidence of and Risk Factors for Fibrosing Colonopathy in US Patients With Cystic Fibrosis Treated With Pancreatic Enzyme Replacement Therapy: A Harmonized Protocol Across Sponsors(The CF-FC Study)
Lead sponsor
AbbVie
Phase
Observational
Overall status
Terminated
Start date
July 31, 2012
Completion date
April 8, 2020
Enrollment
17 (actual)
Sites
123

Conditions

As the registry lists them; a condition with its own page is linked.

fibrosing colonopathy